Empagliflozin + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myocardial Infarction
Conditions
Myocardial Infarction
Trial Timeline
Dec 16, 2020 → Nov 5, 2023
NCT ID
NCT04509674About Empagliflozin + Placebo
Empagliflozin + Placebo is a phase 3 stage product being developed by Eli Lilly for Myocardial Infarction. The current trial status is completed. This product is registered under clinical trial identifier NCT04509674. Target conditions include Myocardial Infarction.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04509674 | Phase 3 | Completed |
| NCT03448406 | Phase 3 | Completed |
| NCT03448419 | Phase 3 | Completed |
| NCT03332212 | Phase 3 | Completed |
| NCT03057977 | Phase 3 | Completed |
| NCT03057951 | Phase 3 | Completed |
| NCT03050229 | Approved | Completed |
| NCT02580591 | Phase 3 | Completed |
Competing Products
20 competing products in Myocardial Infarction